SOURCE: The Bedford Report

The Bedford Report

August 12, 2011 08:16 ET

Big Pharma to Shift Focus to Biotech Firms Such as AEterna Zentaris and ADVENTRX

The Bedford Report Provides Equity Research on AEterna Zentaris and ADVENTRX

NEW YORK, NY--(Marketwire - Aug 12, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation, and discoveries continue to elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ) and ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX). Access to the full company reports can be found at:

www.bedfordreport.com/AEZS

www.bedfordreport.com/ANX

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill their pipelines, which has been a net positive for small biotech companies.

According to Thomson Reuters, on average biotech companies in the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D in 2010, reflecting a 7 percent decline from 2009.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

AEterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.

ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing product candidates for the treatment of cancer.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.

Contact Information